Rapid drug susceptibility testing of drug-resistant mycobacterium tuberculosis isolates directly from clinical samples by use of amplicon sequencing: A proof-of-concept study

Journal of Clinical Microbiology

Volumn 54, Issue 8, 2016, Pages 2058-2067

  Colman, Rebecca E ^a   Anderson, Julia ^a   Lemmer, Darrin ^a   Lehmkuhl, Erik ^a   Georghiou, Sophia B ^b   Heaton, Hannah ^a   Wiggins, Kristin ^a   Gillece, John D ^a   Schupp, James M ^a   Catanzaro, Donald G ^c   Crudu, Valeriu ^d   Cohen, Ted ^e   Rodwell, Timothy C ^b   Engelthaler, David M ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SAN DIEGO   (United States)

^c UNIVERSITY OF ARKANSAS   (United States)

^d Microbiology and Morphology Laboratory   (Moldova)

^e YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BACTERIAL DNA; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; DRUG;

ALLELE; AMPLICON; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOANALYSIS; BACTERIUM ISOLATE; CONTROLLED STUDY; DATA ANALYSIS; DNA SEQUENCE; DRUG RAPID TEST; DRUG RESISTANT TUBERCULOSIS; GENETIC VARIABILITY; HUMAN; INTERMETHOD COMPARISON; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; NEXT GENERATION SEQUENCING; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SPUTUM EXAMINATION; WILD TYPE; ADOLESCENT; ADULT; AGED; CHILD; EVALUATION STUDY; FEMALE; GENETICS; GENOTYPING TECHNIQUE; HIGH THROUGHPUT SEQUENCING; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; SPECIMEN HANDLING; SPUTUM; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PHARMACEUTICAL PREPARATIONS; PILOT PROJECTS; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING; SPUTUM; TIME FACTORS; YOUNG ADULT;

EID: 84979555481     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00535-16     Document Type: Article

References (48)

1. WHO. 2015. Global tuberculosis report 2015. World Health Organization, Geneva, Switzerland. http://apps. who. int/iris/bitstream/10665 /191102/1/9789241565059-eng. pdf.
2. WHO. 2013. Global tuberculosis report 2013. Report WHO/HTM/TB/ 2013. 11. World Health Organization, Geneva, Switzerland. http://apps . who. int/iris/bitstream/10665/91355/1/9789241564656-eng. pdf.
3. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard, vol 23. M24-A. National Committee for Clinical Laboratory Standards, Villanova, P.A.
4. WHO. 2008. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Report WHO/HTM/TB/2008. 392. World Health Organization, Geneva, Switzerland. http://apps. who. int /iris/bitstream/10665/70500/1/WHO-HTM-TB-2008. 392-eng. pdf.
5. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against secondline drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 12:1449-1455.
6. Ling Di, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32:1165-1174. http://dx. doi. org/10. 1183/09031936. 00061808.
7. Barnard M, Gey van Pittius NC, van Helden PD, Bosman M, Coetzee G, Warren RM. 2012. The diagnostic performance of the GenoType MTBDRplus version 2 line probe assay is equivalent to that of the Xpert MTB/RIF assay. J Clin Microbiol 50:3712-3716. http://dx. doi. org/10. 1128 /JCM. 01958-12.
8. WHO. 2008. WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). World Health Organization, Geneva, Switzerland. http: //www. who. int/tb/features-archive/policy
9. WHO. 2013. WHOpolicy statement: the use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. World Health Organization, Geneva, Switzerland. http://apps. who. int /iris/bitstream/10665/78099/1/WHO-HTM-TB-2013. 01. eng. pdf.
10. Pholwat S, Liu J, Stroup S, Gratz J, Banu S, Rahman SM, Ferdous SS, Foongladda S, Boonlert D, Ogarkov O, Zhdanova S, Kibiki G, Heysell S, Houpt E. 2015. Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. mBio 6(2):e02273-14. http://dx. doi. org/10. 1128 /mBio. 02273-14.
11. Piatek AS, Telenti A, Murray MR, El-Hajj H, Jacobs WR, Jr, Kramer FR, Alland D. 2000. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 44:103-110. http: //dx. doi. org/10. 1128/AAC. 44. 1. 103-110. 2000.
12. Chernyaeva EN, Shulgina MV, Rotkevich MS, Dobrynin PV, Simonov SA, Shitikov EA, Ischenko DS, Karpova IY, Kostryukova ES, Ilina EN, Govorun VM, Zhuravlev VY, Manicheva OA, Yablonsky PK, Isaeva YD, Nosova EY, Mokrousov IV, Vyazovaya AA, Narvskaya OV, Lapidus AL, O'Brien SJ. 2014. Genome-wide Mycobacterium tuberculosis vari-ation (GMTV) database: a new tool for integrating sequence variations and epidemiology. BMC Genomics 15:308. http://dx. doi. org/10. 1186 /1471-2164-15-308.
13. Coll F, McNerney R, Preston MD, Guerra-Assuncao JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, Perdigao J, Viveiros M, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark TG. 2015. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med 7:51. http://dx. doi. org/10 . 1186/s13073-015-0164-0.
14. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford AB, Marais BJ, Sintchenko V. 2015. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 70:1198-1202.
15. Köser CU, Bryant JM, Becq J, Torok ME, Ellington MJ, Marti-Renom MA, Carmichael AJ, Parkhill J, Smith GP, Peacock SJ. 2013. Wholegenome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 369:290-292. http://dx. doi. org/10. 1056/NEJMc1215305.
16. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, Pond MJ, Pope CF, Planche TD, Stoker NG, Cosgrove CA, Butcher PD, Harrison TS, Hinds J. 2015. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol 53:1473-1483. http://dx. doi. org/10. 1128/JCM. 02993-14.
17. Kohl TA, Diel R, Harmsen D, Rothgänger J, Walter KM, Merker M, Weniger T, Niemann S. 2014. Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach. J Clin Microbiol 52:2479-2486. http://dx. doi. org/10. 1128/JCM . 00567-14.
18. Niemann S, Koser CU, Gagneux S, Plinke C, Homolka S, Bignell H, Carter RJ, Cheetham RK, Cox A, Gormley NA, Kokko-Gonzales P, Murray LJ, Rigatti R, Smith VP, Arends FP, Cox HS, Smith G, Archer JA. 2009. Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS One 4:e7407. http://dx. doi. org/10. 1371/journal. pone. 0007407.
19. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 35: 907-914.
20. Colman RE, Schupp JM, Hicks ND, Smith DE, Buchhagen JL, Valafar F, Crudu V, Romancenco E, Noroc E, Jackson L, Catanzaro DG, Rodwell TC, Catanzaro A, Keim P, Engelthaler DM. 2015. Detection of low-level mixed-population drug resistance in Mycobacterium tuberculosis using high fidelity amplicon sequencing. PLoS One 10:e0126626. http://dx . doi. org/10. 1371/journal. pone. 0126626.
21. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. 2009. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 33:368-374.
22. Folkvardsen DB, Thomsen VO, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E. 2013. Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods. J Clin Microbiol 51:4220-4222. http://dx. doi. org/10 . 1128/JCM. 01602-13.
23. Rinder H, Mieskes KT, Loscher T. 2001. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 5:339-345.
24. Zetola NM, Shin SS, Tumedi KA, Moeti K, Ncube R, Nicol M, Collman RG, Klausner JD, Modongo C. 2014. Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes. J Clin Microbiol 52:2422-2429. http://dx. doi. org/10. 1128/JCM. 02489-13.
25. Zhang Z, Wang Y, Pang Y, Liu C. 2014. Comparison of different drug susceptibility test methods to detect rifampin heteroresistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:5632-5635. http://dx. doi. org/10. 1128/AAC. 02778-14.
26. Kumar P, Balooni V, Sharma BK, Kapil V, Sachdeva KS, Singh S. 2014. High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis (Edinb) 94:73-80. http://dx. doi. org/10. 1016/j. tube. 2013. 10. 001.
27. Catanzaro A, Rodwell TC, Catanzaro DG, Garfein RS, Jackson RL, Seifert M, Georghiou SB, Trollip A, Groessl E, Hillery N, Crudu V, Victor TC, Rodrigues C, Lin GS, Valafar F, Desmond E, Eisenach K. 2015. Performance comparison of three rapid tests for the diagnosis of drug-resistant tuberculosis. PLoS One 10:e0136861. http://dx. doi. org/10 . 1371/journal. pone. 0136861.
28. Hillery N, Groessl EJ, Trollip A, Catanzaro D, Jackson L, Rodwell TC, Garfein RS, Lin SY, Eisenach K, Ganiats TG, Park D, Valafar F, Rodrigues C, Crudu V, Victor TC, Catanzaro A. 2014. The Global Consortium for Drug-Resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 15:434. http://dx. doi. org/10 . 1186/1745-6215-15-434.
29. WHO. 1998. Laboratory services in tuberculosis control. Part III: culture. World Health Organization, Geneva, Switzerland. http://apps. who. int /iris/bitstream/10665/65942/3/WHO-TB-98. 258-(part3). pdf.
30. Garfein RS, Catanzaro DG, Rodwell TC, Avelos E, Jackson L, Kappin J, Evasco H, Rodriques C, Crudu V, Coetzee G, Lin G, Grossel E, Hillery N, Trollip A, Ganiats T, Victor TC, Eisenach K, Valzafar F, Channick J, Qian L, Catanzaro A. 2015. Phenotypic and genotypic diversity in a multinational sample of drug-resistant M. tuberculosis isolates. Int J Tuberc Lung Dis 19:420-427. http://dx. doi. org/10. 5588 /ijtld. 14. 0488.
31. Lin SYG, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP. 2014. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 52:475-482. http://dx. doi. org/10. 1128/JCM . 01821-13.
32. Kircher M, Sawyer S, Meyer M. 2012. Double indexing overcomes inaccuracies in multiplex sequencing on the Illumina platform. Nucleic Acids Res 40:e3. http://dx. doi. org/10. 1093/nar/gkr771.
33. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30:2114-2120. http://dx. doi . org/10. 1093/bioinformatics/btu170.
34. Duwe S, Schweiger B. 2008. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J Virol Methods 153:134-141.
35. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Soo Kim M, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gle MT, Catanzaro A. 2013. Predicting extensively drug-resistant tuberculosis (XDR-TB) phenotypes with genetic mutations. J Clin Microbiol 52:781-789. http://dx. doi. org/10. 1128/JCM. 02701-13.
36. Cambau E, Viveiros M, Machado D, Raskine L, Ritter C, Tortoli E, Matthys V, Hoffner S, Richter E, Perez Del Molino ML, Cirillo DM, van Soolingen D, Bottger EC. 2015. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study. J Antimicrob Chemother 70:686-696. http: //dx. doi. org/10. 1093/jac/dku438.
37. Merker M, Kohl TA, Roetzer A, Truebe L, Richter E, Rusch-Gerdes S, Fattorini L, Oggioni MR, Cox H, Varaine F, Niemann S. 2013. Whole genome sequencing reveals complex evolution patterns of multidrugresistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 8:e82551. http://dx. doi. org/10. 1371/journal. pone. 0082551.
38. Canetti G, Froman S, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L. 1963. Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull World Health Organ 29:565-578.
39. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, Mitchison DA, Rist N, Smelev NA. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 41:21-43.
40. Tukvadze N, Bablishvili N, Apsindzelashvili R, Blumberg HM, Kempker RR. 2014. Performance of the MTBDRsl assay in Georgia. Int J Tuberc Lung Dis 18:233-239. http://dx. doi. org/10. 5588/ijtld. 13. 0468.
41. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. 2012. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 7:e33275. http://dx. doi. org/10. 1371 /journal. pone. 0033275.
42. Liu Q, Via LE, Luo T, Liang L, Liu X, Wu S, Shen Q, Wei W, Ruan X, Yuan X, Zhang G, Barry CE, Gao Q. 2015. Within patient microevolution of Mycobacterium tuberculosis correlates with heterogeneous responses to treatment. Sci Rep 5:17507. http://dx. doi. org/10. 1038 /srep17507.
43. Black PA, de Vos M, Louw GE, van der Merwe RG, Dippenaar A, Streicher EM, Abdallah AM, Sampson SL, Victor TC, Dolby T, Simpson JA, van Helden PD, Warren RM, Pain A. 2015. Whole genome sequencing reveals genomic heterogeneity and antibiotic purification in Mycobacterium tuberculosis isolates. BMC Genomics 16:857. http://dx. doi. org/10 . 1186/s12864-015-2067-2.
44. Mariam SH, Werngren J, Aronsson J, Hoffner S, Andersson Di. 2011. Dynamics of antibiotic resistant Mycobacterium tuberculosis during longterm infection and antibiotic treatment. PLoS One 6:e21147. http://dx. doi . org/10. 1371/journal. pone. 0021147.
45. Bravo LT, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, Gordon SM, Hall GS, Shrestha NK. 2009. Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol 47:3985-3990. http://dx. doi. org /10. 1128/JCM. 01229-09.
46. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. 2006. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by pyrosequencing technology. J Clin Microbiol 44:1925-1929. http: //dx. doi. org/10. 1128/JCM. 02210-05.
47. Marttila HJ, Makinen J, Marjamaki M, Soini H. 2009. Prospective evaluation of pyrosequencing for the rapid detection of isoniazid and rifampin resistance in clinical Mycobacterium tuberculosis isolates. Eur J Clin Microbiol Infect Dis 28:33-38. http://dx. doi. org/10. 1007/s10096-008-0584-5.
48. Zheng R, Zhu C, Guo Q, Qin L, Wang J, Lu J, Cui H, Cui Z, Ge B, Liu J, Hu Z. 2014. Pyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patients. BMC Infect Dis 14:200. http://dx. doi. org/10 . 1186/1471-2334-14-200.